Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

Oncotarget

Volumn 8, Issue 33, 2017, Pages 55575-55581

  Brandes, Alba A ^a   Finocchiaro, Gaetano ^b   Zagonel, Vittorina ^c   Reni, Michele ^d   Fabi, Alessandra ^e   Caserta, Claudia ^f   Tosoni, Alicia ^a   Eoli, Marica ^b   Lombardi, Giuseppe ^c   Clavarezza, Matteo ^g   Paccapelo, Alexandro ^a   Bartolini, Stefania ^a   Cirillo, Luigi ^h   Agati, Raffaele ^h   Franceschi, Enrico ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f S MARIA HOSPITAL   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h BELLARIA HOSPITAL   (Italy)

Author keywords

Bevacizumab; ETS; Fotemustine; Glioblastoma; RANO

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FOTEMUSTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSESSMENT; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTICENTER STUDY; NEURORADIOLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 85020915359     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15735     Document Type: Article

References (25)

1. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet Oncology. 2014; 15:943-953
2. Wick W, Brandes A, Gorlia T, Bendszus M, Sahm F, Taal W, Taphoorn M, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, et al. LB-05PHASE III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the eortc 26101 trial. Neuro-oncol. 2015; 17:v1
3. Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-oncology. 2016; 18:1304-1312
4. Jaeckle KA, Wu W, Kosel M, Flynn PJ, Buckner JC. Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials Journal of Clinical Oncology. 2008; 26:2024
5. Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M, Stupp R. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. European journal of cancer. 2012; 48:896-903
6. Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. Journal of clinical oncology. 2013; 31:3764-3775
7. Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with firstline chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of oncology. 2015; 26:1188-1194
8. Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. The Lancet Oncology. 2016; 17:1426-1434
9. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology. 2010; 28:1963-1972
10. Lusted LB. Signal detectability and medical decisionmaking. Science. 1971; 171:1217-1219
11. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3:32-35
12. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, SchiffD, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neurooncology. 2011; 13:143-151
13. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of clinical oncology. 2015; 33:2735-2744
14. Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Bottcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, et al. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer research. 2016; 76:525-534
15. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014; 82:1684-1692
16. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014; 271:200-210
17. Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro-oncology. 2015; 17:1139-1147
18. Ellingson BM, Bendszus M, Sorensen AG, Pope WB. Emerging techniques and technologies in brain tumor imaging. Neuro-oncology. 2014; 16 Suppl 7:vii12-23
19. Molina D, Perez-Beteta J, Martinez-Gonzalez A, Sepulveda JM, Peralta S, Gil-Gil MJ, Reynes G, Herrero A, De Las Penas R, Luque R, Capellades J, Balana C, Perez-Garcia VM. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PloS one. 2016; 11:e0161484
20. Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Journal of clinical oncology. 2011; 29:3050-3055
21. Friedman HS, Prados MD, Wen PY, Mikkelsen T, SchiffD, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of clinical oncology. 2009; 27:4733-4740
22. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical cancer research. 2016; 22:575-581
23. Reardon DA, Ballman KV, Buckner JC, Chang SM, Ellingson BM. Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neurooncology. 2014; 16 Suppl 7:vii24-35
24. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. Journal of clinical oncology. 2008; 27:740-745
25. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. Journal of clinical oncology. 1990; 8:1277-1280